Loading stock data…
PAVM
$8.53+0.23 (+2.77%)
Market ClosedLast close May 1
PAVmed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PAVmed Inc. in the Healthcare sector is trading at $8.53. The stock is currently near its 52-week low of $6.00, remaining 24.8% below its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why PAVM maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.53
Potential Upside
5%
Whystock Fair Value$8.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$40.50+374.8%
Range$16.00 – $65.00
Fundamentals
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for u...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$59.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-252.42%
Volume
Today's trading volume
17,404
Recent News
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BIOROBO (PRCT) delivered earnings and revenue surprises of -2.43% and +3.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Why The PAVmed (PAVM) Story Is Shifting After A Major Valuation Reset
PAVmed is back in focus after analysts reset their fair value estimate from US$263.00 to US$40.50, a major shift that puts a very different marker on what they see as reasonable upside. Recent research links this change mainly to how models are being built and updated, rather than to one decisive new data point. This distinction matters for how you read the signal. As you read on, you will see what is driving the evolving narrative and how to keep track of it as conditions change. Analyst...
How The PAVmed (PAVM) Narrative Is Shifting After The Latest Analyst Reassessment
PAVmed’s latest analyst update centers on a recalibrated price target, with fair value moving from US$510.00 to US$263.00, a reduction of roughly 48% that materially reshapes the headline valuation. Analysts describe this shift as a reset of key inputs to align the target with their latest research rather than a simple call on where the business should trade next. As you read on, you will see how to interpret this evolving narrative and what to watch for as the story develops. Analyst Price...
PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio Relaunch
PAVmed taps industry veteran Joseph Virgilio to lead its device portfolio relaunch to boost growth, commercialization and long-term shareholder value.
PAVmed Inc. Q4 2025 Earnings Call Summary
Moby summary of PAVmed Inc.'s Q4 2025 earnings call